Log In
Print this Print this

lixivaptan (Lixar) (CRTX 080)

Also known as: formerly VPA-985

  Manage Alerts
Collapse Summary General Information
Company Chiesi Farmaceutici S.p.A.
DescriptionSelective vasopressin V2 receptor antagonist
Molecular Target Vasopressin 2 (V2) receptor
Mechanism of ActionVasopressin 2 (V2) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationHyponatremia
Indication DetailsTreat hyponatremia; Treat hyponatremia in patients with acute heart failure
Regulatory Designation U.S. - Undisclosed Review (Treat hyponatremia)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today